Cao Yaoquan, Tang Haibo, Wang Guohui, Li Pengzhou, Song Zhi, Li Weizheng, Sun Xulong, Zhong Xiaoxiao, Yu Qianqian, Zhu Shaihong, Zhu Liyong
Department of General Surgery, Third Xiangya Hospital, Central South University, Changsha, 410013, China.
Cell Death Discov. 2023 Sep 25;9(1):351. doi: 10.1038/s41420-023-01622-8.
The inhibitor of apoptosis protein survivin has a critical regulatory role in carcinogenesis and treatment tolerance in colorectal cancer (CRC). However, the targeted drugs for survivin protein are extremely limited. In the present research, we discovered that Tanshinone IIA (Tan IIA) played a dual regulatory role in inhibiting tumorigenesis and reversing 5-Fu tolerance via modulating the expression and phosphorylation of survivin in CRC cells. Mechanistically, Tan IIA suppressed the Akt/WEE1/CDK1 signaling pathway, which led to the downregulation of survivin Thr34 phosphorylation and destruction of the interaction between USP1 and survivin to promote survivin ubiquitination and degradation. Furthermore, Tan IIA significantly facilitated chemoresistant CRC cells to 5-Fu sensitivity. These results revealed that Tan IIA possessed a strong antitumor activity against CRC cells and could act as an up-and-coming agent for treating CRC and overcoming chemotherapy resistance.
凋亡抑制蛋白survivin在结直肠癌(CRC)的致癌作用和治疗耐受性中起着关键的调节作用。然而,针对survivin蛋白的靶向药物极其有限。在本研究中,我们发现丹参酮IIA(Tan IIA)通过调节CRC细胞中survivin的表达和磷酸化,在抑制肿瘤发生和逆转5-氟尿嘧啶(5-Fu)耐受性方面发挥双重调节作用。机制上,Tan IIA抑制Akt/WEE1/CDK1信号通路,导致survivin苏氨酸34磷酸化下调,并破坏USP1与survivin之间的相互作用,从而促进survivin的泛素化和降解。此外,Tan IIA显著增强了化疗耐药的CRC细胞对5-Fu的敏感性。这些结果表明,Tan IIA对CRC细胞具有强大的抗肿瘤活性,可作为一种有前途的药物用于治疗CRC和克服化疗耐药性。